We are thrilled to announce that NunaBio has won the Accelerating Innovation Award at the prestigious CPHI Pharma Awards 2025, held during this year’s CPHI Frankfurt conference.
The CPHI Pharma Awards are among the most respected accolades in the global pharmaceutical and biotechnology sector. With hundreds of entries submitted across 13 categories, the awards celebrate the companies and individuals driving transformative progress in drug development, manufacturing, sustainability, and patient-centred innovation. This year’s ceremony brought together leaders from across the industry to honour the breakthroughs shaping the future of healthcare.
NunaBio’s win in the Accelerating Innovation category recognises our pioneering work in custom DNA manufacture using technology that is capable of producing high-purity, complex DNA at scale, both faster and more sustainably than traditional methods.
This award is a testament to the dedication and ingenuity of the entire NunaBio team. From our scientists to our commercial and operations teams, every member of the company has played a vital role in bringing this technology to life. We also extend our sincere congratulations to the other shortlisted companies in the Accelerating Innovation category. Being recognised alongside such outstanding innovators is an honour in itself.
CEO and founder, Joe Hedley had this to say:
“Winning the Accelerating Innovation Award at CPHI is a proud moment for NunaBio. This recognition from one of the industry’s most respected platforms validates our belief that synthetic DNA can, and should, move faster, be more accessible, and deliver real-world impact. I’m incredibly proud of our, together we’re helping to shape the future of this industry.”
Winning at CPHI Frankfurt marks a major milestone for NunaBio and we look forward to continuing our journey of innovation and collaboration. We thank the CPHI judging panel and organisers for this incredible recognition!
